RUNX1 Research Acceleration Grant Programme (RARE)

105

ACTIONS

ShareTweetWhatsappEmail

Deadline: 4-Dec-23

The RUNX1 Research Program and Alex's Lemonade Stand Foundation are excited to launch the Exploration Grant Program for Research Speeding up RUNX1 (RARE) to finance research that will accelerate the discovery of drug-mediated oncogenic pathways and provide cancer interception and cancer prevention therapeutics for children e family members RUNX1-FPD.

PREMIUM SUBSCRIPTION ACCESS

Download free ebooks on "Grant Opportunities without Deadlines" and "New and Innovative Ideas for Fundraising"JUNTAR

Programme Description

• The Research Accelerating RUNX1 Exploration Grant is a prize A two-year project designed to fund research that will lead to the development of therapies for patients with RUNX1-FPD that will intercept the transition from a pre-cancer state (clonal hematopoiesis) to MDS/AML or cancer prevention (before clonal hematopoiesis).
• The RUNX1 Research Programme hosts an annual scientific meeting that brings together fellows and other scientists. Grant recipients are expected to present their progress as part of the annual review.

Scope

• The objectives of research proposals must be relevant to the goal of preventing hematological malignancies in RUNX1-FPD. Proposals that seek to move from the laboratory to the bedside will be given priority.
• The following research areas are prioritized and are not ranked in any particular order:
  • Drug Repurposing and Clinical Translation
    • Support for preclinical experiments and related clinical studies designed to test regulatory-approved agents for RUNX1-FPD hematopoietic function rescue and high-risk clonal hematopoiesis interception.
  • RUNX1 Biology
    • To characterize the normal function of RUNX1 and the function of mutant germline RUNX1 proteins. There is significant interest in defining the role of RUNX1 in DNA damage repair in HSCs and the potential role that germline RUNX1 mutations may play in the acquisition of somatic mutations.
    • To identify regulators of RUNX1 expression and function in order to discover new methods for correcting RUNX1 function within the hematopoietic system.

Information on financing

• The requested budget must be proportional to the scope of the proposed project and must be equal to or less than US$250,000 in direct costs over 2 years. A maximum of US$125,000 in total costs may be requested per year.

Eligibility Criteria

• Candidate institutions may be based in the U.S. or outside the U.S. Candidates do not need to be citizens. from the United StatesThe funds should be granted to non-profit institutions or organizations.
• Candidates must hold an MD, PhD, or MD/PhD (DO, MBBS, or equivalent).
• Candidates may receive research grants from other funding sources during the grant period, but there must be clear documentation of the mechanisms to avoid scientific and budgetary overlaps.
• Candidates should have research experience and in-depth knowledge of normal or malignant hematopoiesis and/or immunology.

Selection criteria

• The selection criteria include the following:
  • Background/schooling;
  • Publication record;
  • Granting of scholarships and recognition/acknowledgments of research;
  • Quality and overall rating of the research proposal based on the NIH's 9-point scoring system;
  • Evidence of collaboration within the project proposal – An important sub-objective is to stimulate research progress through collaborations between research groups;
  • Alignment with the overall goal of preventing hematological malignancies in RUNX1-FPD and the feasibility of translating the findings to clinical practice.

For more information, visit ALSF.